Blood Res.  2021 Apr;56(S1):S1-S4. 10.5045/br.2021.2020320.

Novel combination immunochemotherapy beyond CD20 for B-cell lymphomas

• Yi JH

• KMID: 2515292
• DOI: http://doi.org/10.5045/br.2021.2020320

Abstract

Despite substantially improved survival with rituximab-based treatment regimens, there is an unmet medical need for better treatments of B-cell lymphoma, particularly for patients with relapsed or refractory disease. Retreatment with rituximab exerts a limited effect in these patients, and platinum-based salvage treatment followed by autologous stem cell transplantation remains the only curative option. Recent strategies have focused on targeting novel B-cell surface markers, inhibiting B-cell receptor signaling, and enhancing the cytotoxicity of effector cells. The current article will review the recent progress in immunochemotherapy targeting other than CD20 for B-cell lymphomas.

Keyword

B-cell lymphoma; CD19; CD22; CD79b